Emphasis on Collaboration and Innovation in Clinical Research
Senior executives and the clinical research team from Nobel Pharmaceuticals, one of Turkey’s leading pharmaceutical companies, visited our IEU Medicalpoint Phase 1 Clinical Research Center (KAM) and Prof. Dr. Ahmet Uğur Yılmaz Clinical Research Center (Phase 2-3).
This meaningful visit took place on December 10, 2025, and was attended by Nobel Pharmaceuticals Medical Director Aybige Pilancı, Clinical Research & Pharmacovigilance Team Manager Belkıs Sağıroğlu, and the clinical research team.
The main agenda items of the visit were the current status of clinical research in Turkey, future collaboration potentials, and innovative approaches in drug development processes. Medical Point Phase 1 KAM officials gave a detailed presentation on the center’s infrastructure, which meets international standards, and its experienced staff.
The Nobel Pharmaceuticals delegation expressed their satisfaction at having the opportunity to observe the units of MedicalPoint KAM (Phase 1 center and Phase 2-3 centers) on site. During the discussions, the determination to develop joint strategies, particularly regarding accelerating domestic drug development processes and increasing Turkey’s global competitiveness in the field of clinical research, was emphasized.
This visit once again highlighted Nobel Pharmaceuticals’ commitment to clinical research and Medical Point KAM’s key role in the sector. The potential collaboration between the two institutions is expected to make significant contributions to the drug development ecosystem in Turkey.